1. Inicio
  2. Publicaciones
  3. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bastos-Oreiro, M
  • Iacoboni, G
  • Garcés, VN
  • Caballero, AC
  • Martínez, N
  • Delgado, J
  • Kwon, M
  • de Villambrosia, S
  • Hernani, R
  • Jimenez-Ubieto, A
  • Bailen, R
  • Zaberio, I
  • García-Sancho, A
  • Barba, P

Grupos

Abstract

[No abstract available]

Datos de la publicación

ISSN/ISSNe:
2572-9241, 2572-9241

HemaSphere  WILEY

Tipo:
Letter
Páginas:
-
PubMed:
39906687
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,108 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • atezolizumab; axicabtagene ciloleucel; bendamustine; cyclophosphamide; glofitamab; lactate dehydrogenase; lenalidomide; lisocabtagene maraleucel; pembrolizumab; polatuzumab vedotin; programmed death 1 ligand 1; programmed death 1 receptor; rituximab; tafasitamab; tisagenlecleucel T; adult; antigenic escape; autologous stem cell transplantation; cancer survival; chimeric antigen receptor T-cell immunotherapy; cytokine release syndrome; disease exacerbation; female; hemophagocytic syndrome; human; Letter; major clinical study; male; monotherapy; mutation; overall survival; progression free survival; retrospective study; T cell/histiocyte-rich large B cell lymphoma; treatment outcome

Cita

Compartir